


Hypothalamic Neurofibrosis: A New Player in the Fight Against Metabolic Disease

Cait A Beddows¹, Feiyue Shi¹, Anna Horton^{2,3}, Sagar Dalal⁴, Ping Zhang⁵, Chang-Chun Ling⁵, V. Wee Yong⁶, Kim Loh⁷, Ellie Cho⁸, Adam J Rose⁹, Magdalene K Montgomery¹, Nicki Packer⁴, Matthew Watt¹, Benjamin L Parker¹, Robyn Brown^{2,3}, Edward SX Moh⁴, **Garron T Dodd^{1*}**

- ¹ Department of Anatomy and Physiology, The University of Melbourne, Parkville, Melbourne, Australia.
- ² Department of Biochemistry and Pharmacology, University of Melbourne, Parkville, Melbourne, Australia.
- ³ Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Melbourne.
- ⁴ School of Natural Sciences, Macquarie University, Australia.
- ⁵ Department of Chemistry, University of Calgary, Canada
- ⁶ Department of Clinical Neurosciences and the Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Canada.
- ⁷ St. Vincent's Institute of Medical Research, Fitzroy, Australia.
- ⁸ Biological Optical Microscopy Platform, The University of Melbourne, Parkville, Australia.

Metabolic diseases such as obesity and Type-2 diabetes are characterised by insulin resistance. Cells within the arcuate nucleus of the hypothalamus (ARC) become insulin resistant and are a key regulator of metabolic dysfunction but the mechanisms are incompletely understood. Here, we identify a specialised chondroitin sulfate proteoglycan extracellular matrix (CSPG-ECM) that encapsulates neuronal populations in the ARC. Remodelling of the CSPG-ECM during the progression of metabolic diseases drives neurofibrosis, insulin resistance and metabolic dysfunction. We show that decreased CSPG-ECM turnover in the ARC is a hallmark of obesity and other metabolic diseases. Enzymatic- or small molecule-induced disassembly of CSPG-ECM within the ARC of obese/insulin-resistant mice enhances insulin infiltration into the brain, promoting the remission of neuronal insulin resistance and improved metabolic health. Our study identifies neurofibrosis as a fundamental mechanism underlying the development of obesity and insulin resistance and presents a therapeutic strategy for treating metabolic diseases.



⁹ Dept of Biochemistry & Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Australia.